Home Stock

Stock Research: ScinoPharm

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

ScinoPharm

TAI:1789 TW0001789006
26
  • Value
    3
  • Growth
    55
  • Safety
    Safety
    55
  • Combined
    22
  • Sentiment
    39
  • 360° View
    360° View
    26
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ScinoPharm Taiwan Ltd. researches, develops, manufactures, and sells active pharmaceutical ingredients. The company operates in the pharmaceutical industry. It serves markets in the Americas, Europe, Australia, and Asia. In the last fiscal year, the company had a market cap of $445 million, profits of $40 million, and revenue of $104 million. The number of employees is not available.

more

ANALYSIS: With an Obermatt 360° View of 26 (better than 26% compared with alternatives), overall professional sentiment and financial characteristics for the stock ScinoPharm are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for ScinoPharm. The consolidated Growth Rank has a good rank of 55, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 55% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 55 which means that the company has a financing structure that is safer than 55% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 3 which means that the share price of ScinoPharm is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 97% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 39, which means that professional investors are more pessimistic about the stock than for 61% of alternative investment opportunities. ...read more

more
Strongest Rank Price vs. Earnings (P/E)
Weakest Rank Capital Growth
Country Taiwan
Industry Pharmaceuticals
Size Small
Website scinopharm.com.tw
Index
ScinoPharm stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 23-Jun-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
3 18 24 41
Growth
55 37 9 81
Safety
Safety
55 69 78 67
Sentiment
39 42 22 1
360° View
360° View
26 33 14 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
12 12 20 24
Opinions Change
50 50 1 50
Pro Holdings
n/a 40 20 41
Market Pulse
75 87 100 1
Sentiment
39 42 22 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
3 18 24 41
Growth
55 37 9 81
Safety Safety
55 69 78 67
Combined
22 30 20 67
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
9 16 13 26
Price vs. Earnings (P/E)
1 12 7 36
Price vs. Book (P/B)
37 35 41 65
Dividend Yield
1 36 49 53
Value
3 18 24 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
32 66 26 96
Profit Growth
17 20 10 84
Capital Growth
92 28 26 8
Stock Returns
83 48 51 61
Growth
55 37 9 81
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
81 67 71 68
Refinancing
24 49 65 67
Liquidity
58 55 63 41
Safety Safety
55 69 78 67

Similar Stocks

Discover high‑ranked alternatives to ScinoPharm and broaden your portfolio horizons.

Tripod Technology

TAI:3044
Country: Taiwan
Industry: Electronic Components
Size: Medium
Full Stock Analysis

Phison Electronics

TWO:8299
Country: Taiwan
Industry: Semiconductors
Size: Medium
Full Stock Analysis

Highwealth Construction

TAI:2542
Country: Taiwan
Industry: Real Estate Development
Size: Medium
Full Stock Analysis

Nippon Shinyaku

TYO:4516
Country: Japan
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews